---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-23-000033"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T16:46:38.631225+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Altimmune Q2 net loss $16.1M; pemvidutide obesity trial data expected Q4 2023

## Summary
- Net loss of $16.1M ($0.32/share) vs $20.1M ($0.42/share) in Q2 2022.
- Cash, equivalents & short-term investments totaled $160.0M as of June 30, 2023.
- R&D expenses $13.3M, G&A $4.8M for the quarter.
- Top-line 48-week MOMENTUM Phase 2 obesity trial results expected Q4 2023.
- Enrollment commenced in IMPACT Phase 2b NASH trial; top-line data expected Q1 2025.

## SEC filing metadata
- accession: 0001326190-23-000033
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000033/0001326190-23-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000033/alt-20230810x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-23-000033
- JSON: https://secwatch.observer/filing/0001326190-23-000033.json
- Plain text: https://secwatch.observer/filing/0001326190-23-000033.txt

## Key facts
- Earnings Releases
  Altimmune, Inc. reported the three months ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was $16.1 million, or $0.32 net loss per share, EPS $0.32 net loss per share.
  - Period: the three months ended June 30, 2023
  - Net income: Net loss for the three months ended June 30, 2023 was $16.1 million, or $0.32 net loss per share
  - EPS: $0.32 net loss per share
  - Result: reported results
  source text: Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000033/0001326190-23-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.